How BTK activity corresponds to the differentiation of CXCR3-expressing (T-bet+) B cells in MS and whether evobrutinib targets the brain-homing and antibody-producing potential of these B cells is unknown. The gene discussed is BTK; the disease is myeloid sarcoma.